Biotransformation of clozapine in humans

Drug Metabolism and Disposition

Volumn 25, Issue 5, 1997, Pages 603-609

  Dain, Jeremy G ^a   Nicoletti, Joseph ^b   Ballard, Frances ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE; DRUG METABOLITE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CLOZAPINE; FECES; HUMANS; MALE;

EID: 0030952034     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. J. Claghorn, G. Honigfeld, F. S. Abuzzahab, Sr., R. Wang, R. Steinbook, V. Tuason, and G. Klerman: The risks and benefits of clozapine versus chloropromazine. J. Clin. Psychopharmacol 7, 377-384 (1987).
2. J. Kane, G. Honigfeld, J. Singer, H. Meltzer, and the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45, 789-796 (1988).
3. H. Weigmann and C. Hiemke: Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 583, 209-216 (1992).
4. M.-C. Chung, S.-K. Lin, W.-H. Chang, M. W. Jann: Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 613, 168-173 (1993).
5. M. Hasegawa, R. Gutierrez-Esteinou, L. Way, and H. Y. Meltzer: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J. Clin. Pharmacol. 13, 383-390 (1993).
6. S. A. Volpicelli, F. Centorrino, P. R. Puopolo, J. Kando, F. R. Frankenburg, R. J. Baldessarini, and J. G. Flood: Determination of clozapine, norclozapine, and clozapine N-oxide in serum by liquid chromatography. Clin. Chem. 39, 1656-1659 (1993).
7. S.-K. Lin, W.-H. Chang, M.-C. Chung, Y. W. F. Lam, and M. W. Jann: Disposition of clozapine and desmethylclozapine in schizophrenic patients. J. Clin. Pharmacol. 34, 318-324 (1994).
8. F. Centorrino, R. J. Baldessarini, J. C. Kando, F. R. Frankenburg, S. A. Volpicelli, and J. G. Flood: Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J. Clin. Psychopharmacol. 14, 119-125 (1994).
9. R. Gauch and W. Michaelis: The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine) in mice, dogs, and human subjects. Il Farmaco-Ed. Pr. 26, 667-681 (1970).
10. M. W. Jann, Y. W. F. Lam, and W.-H. Chang: Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Arch. Int. Pharmacodyn. 328, 243-250 (1994).
11. 3-bei der metabolisierung des clozapine in Menschlichen Korper. Arzneim. Forsch. 27, 982-990 (1977).
12. G. McKay, G-Q. Zhang, N. Pidskalny, and K. K. Midha: Application of ESI-MS to the identification of new metabolites of clozapine. In "Proceedings the 42nd ASMS Conference on Mass Spectrometry and Allied Topics," May 29-June 3, 1994, p. 346.
13. +-glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biol. Mass Spectrom. 23, 147-148 (1994).
14. M. G. Choc, F. Hsuan, G. Honigfeld, W. T. Robinson, L. Ereshefsky, M. L. Crismon, S. R. Saklad, J. Hirschowitz, and R. Wagner: Single-vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm. Res. 7, 347-351 (1990).
15. M. G. Choc, R. G. Lehr, F. Hsuan, G. Honigfeld, H. T. Smith, R. Borison, and J. Volavka: Multiple-dose pharmacokinetics of clozapine in patients. Pharm. Res. 4, 402-405 (1987).
16. L. Ereshefsky, M. W. Jann, S. R. Saklad, and C. M. Davis: Bioavailability of psychotropic drugs: historical perspective and pharmacokinetics overview. J. Clin. Psychiatry 47, (Suppl. 9) 6-15 (1986).
17. G.-Q. Zhang, G. McKay, J. W. Hubbard, and K. K. Midha: Application of electrospray mass spectrometry to the identification of intact glucuronide and sulphate conjugates of clozapine in the rat. Xenobiotica 26, 541-550 (1996).
18. 3 receptor antagonist. Drug Metab. Dispos. 23, 806-812 (1995).
19. R. M. Barbhaiya, K. A. Dandekar, and D. S. Greene: Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Drug Metab. Dispos. 24, 91-95 (1996).
20. K. Brøsen, E. Skjelbo, B. B. Rasmussen, H. E. Poulsen, and S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45, 1211-1214 (1993).
21. M. Jerling, L. Lindström, U. Bondesson, L. Bertilsson: Fluvoxamine inhibition and carbemazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther. Drug Monit. 16, 368-374 (1994).
22. C. Hiemke, H. Weigmann, S. Härtter, N. Dahmen, H. Wetzel, and H. Müller: Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 14, 279-281 (1995).
23. L. Bertilsson, J. A. Carrillo, M-L Dahl, A. Llerena, C. Alm, U. Bondesson, L. Lindström, I. R. De La Rubia, S. Ramos, and J. Benitez: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38, 471-473 (1994).
24. M. J. Arranz, E. Dawson, S. Shaikh, P. Sham, T. Sharma, K. Aitchison, M. A. Crocq, M. Gill, R. Kerwin, and D. A. Collier: Cytochrome P4502D6 genotype does not determine response to clozapine. Br. J. Clin. Pharamcol. 38, 417-420 (1994).
25. M-L Dahl, A. Llerna, U. Bondesson, L. Lindström, and L. Bertilsson: Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin. Pharmacol. 37, 71-74 (1994).
26. M. Pirmohamed, D. Williams, S. Madden, E. Templeton, and B. K. Park: Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272, 984-990 (1995).
27. F. Centorrino, R. J. Baldessarini, J. Kando, F. R. Frankenburg, S. A. Volpicelli, P. R. Puopolo, and J. G. Flood: Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am. J. Psychiatry 151, 123-125 (1994).
28. S. Syzmanski, J. A. Lieberman, D. Picou, S. Masiar, and T. Cooper: A case report of cimetidine-induced clozapine toxicity. J. Clin. Psychiatry 52, 21-22 (1991).
29. V. Raitasuo, R. Lehtovaara, and M. O. Huttunen: Carbemazepine and plasma levels of clozapine. Am. J. Psychiatry 150, 169 (1993).
30. D. D. Miller: Effect of phenytoin on plasma clozapine concentrations in two patients. J. Clin. Psychiatry 52, 23-25 (1991).
31. R. Pokorny, M. J. Finkel, and W. T. Robinson: Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm. Res. 11, 1221 (1994).
32. F-D-C Reports, F-D-C Reports, Inc., pp. T&G-6 to T&G-7; Chevy Chase, MD (1995).